



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: NB 2017.00

In re patent application of

SHEPARD, H. MICHAEL et al.

Serial No. 09/910,345

Filed: July 20, 2001

For: METHODS FOR IDENTIFYING THERAPEUTIC TARGETS FOR TREATING
INFECTIOUS DISEASE

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and

3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United


Serial No. 09/910,345

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Nov. 11, 2002

Date



James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021



16

1

SEQUENCE LISTING

<110> SHEPARD, H. MICHAEL
LACKEY, DAVID B.
CATHERS, BRIAN E.
SERGEEVA, MARIA V.

<120> METHODS FOR IDENTIFYING THERAPEUTIC TARGETS FOR
TREATING INFECTIOUS DISEASE

<130> NB-2017.00

<140> 09/910,345
<141> 2001-07-20

<150> 60/219,598
<151> 2000-07-20

<150> 60/244,953
<151> 2000-11-01

<150> 60/276,728
<151> 2001-03-16

<160> 12

<170> PatentIn 2.1

<210> 1
<211> 60
<212> PRT
<213> Pseudomonas aeruginosea

<220>
<221> NON_TER
<222> 1,60

<400> 1
Arg Asn Gly Gly Gln Ile Leu Val Glu Ala Leu Arg Arg Asn Ala Val
1 5 10 15

Asp Thr Val Tyr Cys Ile Pro Gly Glu Ser Tyr Leu Pro Val Leu Asp
20 25 30

Ala Leu Tyr Asp Thr Asp Gly Ile Arg Thr Val Val Thr Arg His Glu
35 40 45

Gly Ala Ala Ser Asn Met Ala Asp Ala Tyr Gly Lys
50 55 60

<210> 2
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artifical Sequence: Sequence comparison
of SEQ ID NO: 1 to SEQ ID NO: 3

<220>
<221> NON_CONS
<222> 1-2,3-4,5-6,6-7,7-8,8-9,9-10,10-11,13-14,14-15,18-19

<400> 2
Arg Gly Gly Leu Arg Val Gly Pro Leu Ala Gly Ile Arg Val Thr Arg
1 5 10 15

His Glu Ala Asp Ala
20

<210> 3
<211> 59
<212> PRT
<213> Homo sapiens

<220>
<221> NON_TER
<222> 1,59

<221> NON_CONS
<222> (34)...(35)

<400> 3
Arg His Gly Gly Glu Asn Val Ala Ala Val Leu Arg Ala His Gly Val
1 5 10 15

Arg Phe Ile Phe Thr Leu Val Gly Gly His Ile Ser Pro Leu Leu Val
20 25 30

Ala Cys Glu Lys Leu Gly Ile Arg Val Val Asp Thr Arg His Glu Val
35 40 45

Thr Gly Val Phe Ala Ala Asp Ala Met Ala Arg
50 55

<210> 4
<211> 60
<212> PRT
<213> Pseudomonas aeruginosea

<220>
<221> NON_TER
<222> 1,60

<400> 4
Leu Thr Gly Arg Pro Gly Ile Cys Phe Val Thr Arg Gly Pro Gly Ala
1 5 10 15

Thr His Ala Ala Asn Gly Val His Thr Ala Gln Gln Asp Ser Thr Pro
20 25 30

Met Ile Leu Phe Val Gly Gln Val Glu Ser Ala Phe Lys Gly Arg Glu
35 40 45

Ala Phe Gln Glu Val Asp Tyr Val Gln Met Phe Ser
50 55 60

<210> 5
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artifical Sequence: Sequence comparison
of SEQ ID NO: 4 to SEQ ID NO: 6

<220>
<221> NON_CONS
<222> 1-2,2-3,3-4,5-6,8-9,9-10,10-11,12-13,13-14,14-15,15-16,16-17,
17-18,18-19,20-21

<400> 5
Leu Gly Gly Val Thr Gly Pro Gly Thr Val Ala Gln Pro Leu Gly Arg
1 5 10 15

Ala Gln Val Asp Phe
20

<210> 6
<211> 60
<212> PRT
<213> Homo sapiens

<220>
<221> NON_TER
<222> 1,60

<400> 6
Leu Ser Gly Thr Val Gly Val Ala Ala Val Thr Ala Gly Pro Gly Leu
1 5 10 15

Thr Asn Thr Val Thr Ala Val Lys Asn Ala Gln Met Ala Gln Ser Pro
20 25 30

Ile Leu Leu Leu Gly Gly Ala Ala Ser Thr Leu Leu Gln Asn Arg Gly
35 40 45

Ala Leu Gln Ala Val Asp Gln Leu Ser Leu Phe Arg
50 55 60

<210> 7
<211> 55
<212> PRT
<213> Pseudomonas aeruginosea

<220>
<221> NON_TER
<222> 1,55

<400> 7
Gly Leu Ala Lys Trp Ala Val Glu Ile Asp Arg Ile Glu Arg Ile Pro
1 5 10 15

Glu Ile Val Gly Arg Ala Phe Ser Val Ala Thr Ser Gly Arg Pro Gly
20 25 30

Pro Val Val Val Ala Leu Pro Glu Glu Ile Leu Phe Gly Ser Ala Gln
35 40 45

Val Ala Asp Ala Pro Glu Pro
50 55

<210> 8
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artifical Sequence: Sequence comparison
of SEQ ID NO: 7 to SEQ ID NO: 9

<220>
<221> NON_CONS
<222> 1-2,2-3,3-4,4-5,5-6,6-7,8-9,12-13,13-14,15-16,16-17,17-18

<400> 8
Leu Lys Val Arg Ile Ala Ser Gly Pro Gly Pro Val Val Leu Pro Leu
1 5 10 15

Val Pro

<210> 9
<211> 55
<212> PRT
<213> Homo sapiens

<220>
<221> NON_TER
<222> 1,55

<221> MOD_RES
<222> (22)
<223> Any Amino Acid

<400> 9
Pro Leu Cys Lys Phe Cys Val Ser Val Pro Arg Val Arg Asp Ile Val
1 5 10 15

Pro Thr Leu Arg Ala Xaa Met Ala Ala Ala Gln Ser Gly Thr Pro Gly
20 25 30

Pro Val Phe Val Glu Leu Pro Val Asp Val Leu Tyr Pro Phe Phe Met
35 40 45

Val Gln Lys Glu Met Val Pro
50 55

<210> 10
<211> 54
<212> PRT
<213> Pseudomonas aeruginosea

<220>
<221> NON_TER
<222> 1,54

<400> 10
Leu Leu Leu Glu Asn Glu Pro Gly Ala Leu Ser Arg Val Val Gly Leu
1 5 10 15
Phe Ser Gln Arg Asn Tyr Asn Ile Glu Ser Leu Thr Val Ala Pro Thr
20 25 30
Glu Asp Pro Thr Leu Ser Arg Leu Thr Leu Thr Thr Val Gly His Asp
35 40 45

Glu Val Ile Glu Gln Ile
50

<210> 11
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Sequence comparison
of SEQ ID NO: 10 to SEQ ID NO: 12

<220>
<221> NON_CONS
<222> 3-4,5-6,6-7,8-9,9-10,10-11,12-13,13-14,15-16,17-18

<400> 11
Leu Leu Leu Pro Gly Leu Arg Asn Asn Ala Asp Pro Leu Gly His Glu
1 5 10 15

Val Ile

<210> 12
<211> 53
<212> PRT
<213> Homo sapiens

<220>
<221> NON_TER
<222> 1,53

<221> NON_CONS
<222> (42) .. (43)

<400> 12
Leu Leu Leu Leu Ser Leu Pro Gly Leu Ala Ala Gly Ile Thr Ile Leu
1 5 10 15
Leu Thr Asp Arg Asn Leu Asn Thr Thr Phe Phe Asp Pro Ala Gly Gly
20 25 30
Gly Asp Pro Ile Leu Tyr Gln His Leu Phe Ile Phe Gly His Pro Glu
35 40 45
Val Tyr Asn Arg Ile
50